Drug intelligence / Profile preview

BNT25006

Development stage: Preclinical
Lead developer: BioNxt Solutions
Modality: Small Molecules, Drug Delivery Systems

Overview

**BNT25006** is an advanced-preclinical BioNxt Solutions oncology program described as a targeted chemotherapy platform incorporating an anticancer small-molecule inhibitor of mechanistic target of rapamycin. The platform is intended to improve targeted delivery of cytotoxic therapies and is reported to be adaptable to more than 100 cytotoxic agents; however, the specific cytotoxic payloads, delivery construct, formulation, route of administration, and detailed molecular pharmacology have not been publicly disclosed. Public drug-development listings identify BNT-25006 as a BioNxt mTOR-inhibitor program for neoplasms at the preclinical stage. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/174d049538cd4ea1a5f8a919b2a712eb))

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on BNT25006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT25006.

Explore the full profile